SLU-PP-332 Explained: What the ERR Agonist Exercise Mimetic Does

A Short Primer

SLU-PP-332 is a small-molecule pan-agonist of the three estrogen-related receptor (ERR) isoforms — ERRα, ERRβ, and ERRγ — developed by researchers at Saint Louis University (from which the “SLU” in the name derives) and described in peer-reviewed literature beginning in the early 2020s. It has generated interest as a pharmacologic “exercise mimetic” — a compound that reproduces meaningful portions of the metabolic program normally induced by endurance exercise.

A clarification worth making up front: despite appearing on some peptide-focused sites, SLU-PP-332 is not a peptide. It is a synthetic small-molecule chemical entity. Most of the physician interest around it has emerged from its inclusion in the broader conversation about peptide and small-molecule strategies for metabolic optimization.

 

How SLU-PP-332 Is Thought to Work

ERRs are a family of orphan nuclear receptors that regulate transcription of genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and skeletal muscle oxidative capacity. Endogenous exercise increases ERR activity in skeletal muscle via the PGC-1α coactivator pathway, driving many of the characteristic metabolic adaptations to endurance training.

SLU-PP-332 binds and activates all three ERR isoforms, producing downstream effects in skeletal muscle and other metabolically active tissues that significantly overlap with the exercise-induced transcriptional program. In published preclinical work, dosed mice show:

• Increased endurance capacity in treadmill testing
• Enhanced fatty acid oxidation
• Increased mitochondrial biogenesis markers
• Improved glucose handling
• Resistance to diet-induced obesity

The published literature frames SLU-PP-332 as a pharmacologic tool for studying ERR biology — and, increasingly, as a potential therapeutic candidate for metabolic disease and conditions where exercise capacity is limited.

 

What Has Been Studied

The bulk of the SLU-PP-332 literature is preclinical. Key features of the dataset:

• Dosing in mice has typically been in the range of 50 mg/kg intraperitoneally
• Oral bioavailability has been reported as limited, which is a meaningful constraint for therapeutic development
• Effects described are largely metabolic — endurance, fatty acid oxidation, body composition — rather than strength or hypertrophy
• A notable cardiovascular signal — increased resting heart rate in treated mice — has been reported in at least one study

As of 2026, human clinical trial activity is emerging but early. There is no FDA-approved human indication for SLU-PP-332, and it is not listed on the 503A bulk drug substances list for compounding use. Access through U.S. compounding pharmacies is therefore not an established pathway.

 

Why the Physician and Longevity Community Is Interested

SLU-PP-332 sits at the intersection of several high-interest areas in modern medical practice:

• Metabolic medicine, where practitioners are actively looking for pharmacologic tools that approximate exercise benefits in patients who cannot reliably exercise
• [Longevity medicine](https://newtropin.com/blog/epitalon-the-longevity-peptide-revolutionizing-anti-aging-medicine/), where mitochondrial biogenesis and improved oxidative capacity are on a short list of intervention targets with plausible age-related-decline reversal implications
• GLP-1 complement strategies, where preserving or improving lean mass and metabolic rate alongside weight loss is a growing focus

The compound’s mechanism — working upstream through a transcriptional nuclear receptor — is a meaningfully different approach from GLP-1 receptor agonism, exercise, or direct mitochondrial cofactor supplementation.

 

What Remains Unknown

For clinicians who field patient questions about SLU-PP-332, the appropriate framing is cautious optimism about the mechanism and realistic acknowledgment of how early the data are. Open questions include:

• Whether the mouse metabolic effects translate to humans at tolerable doses
• What the long-term cardiovascular profile looks like given the tachycardia signal
• How the compound interacts with exercise training versus replaces aspects of it
• Whether any oral-bioavailable analog or alternative delivery format advances into clinical development

 

Key Takeaways

• SLU-PP-332 is a small-molecule pan-ERR agonist, not a peptide.
• It reproduces many of the transcriptional features of endurance exercise in preclinical models.
• The bulk of the published data are mouse studies; human clinical development is early.
• It is not FDA-approved and is not on the 503A bulk drug substances list.
• Cardiovascular effects, particularly increased resting heart rate, deserve close attention in ongoing research.

 

Frequently Asked Questions

What does SLU-PP-332 do?

It activates the three estrogen-related receptor isoforms (ERRα, ERRβ, ERRγ), driving a transcriptional program in skeletal muscle and other metabolic tissues that reproduces many features of the exercise response — including fatty acid oxidation, mitochondrial biogenesis, and increased endurance capacity.

Is SLU-PP-332 a peptide?

No. It is a synthetic small molecule. The confusion is partly due to its appearance alongside peptide therapies in clinical peptide communities.

Has SLU-PP-332 been tested in humans?

Published data are predominantly preclinical. Human clinical trial activity is early and not yet a settled part of the dataset.

Can I get SLU-PP-332 through a compounding pharmacy?

It is not on the FDA 503A bulk drug substances list, and U.S. compounding access is not an established pathway. Research-grade material circulates outside clinical channels and is not an appropriate source for physician-supervised use.

Contact Us